Drug-sensitivity experiments using the FDA-approved BRAF and MEK inhibitors, dabrafenib and trametinib, demonstrated the feasibility of employing melanoma brain metastases patient-derived organoids as models for targeted-therapy in vitro testing and for the discovery of novel therapeutic targets. Here, MAP2K7 is linked to melanoma.